GURUFOCUS.COM » STOCK LIST » USA » NAS » Incyte Corp (NAS:INCY) » Definitions » Price-to-Owner-Earnings
Switch to:

Incyte (NAS:INCY) Price-to-Owner-Earnings

: 28.23 (As of Today)
View and export this data going back to 1993. Start your Free Trial

As of today (2023-04-02), Incyte's share price is $72.27. Incyte's Owner Earnings per Share (TTM) ended in Dec. 2022 was $2.56. It's Price-to-Owner-Earnings for today is 28.23.


The historical rank and industry rank for Incyte's Price-to-Owner-Earnings or its related term are showing as below:

INCY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 27.48   Med: 47.89   Max: 3774.33
Current: 28.29

During the past 13 years, the highest Price-to-Owner-Earnings of Incyte was 3774.33. The lowest was 27.48. And the median was 47.89.


INCY's Price-to-Owner-Earnings is ranked better than
57.14% of 168 companies
in the Biotechnology industry
Industry Median: 37.24 vs INCY: 28.29

As of today (2023-04-02), Incyte's share price is $72.27. Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $1.52. Therefore, Incyte's PE Ratio for today is 47.55.

As of today (2023-04-02), Incyte's share price is $72.27. Incyte's EPS without NRI for the trailing twelve months (TTM) ended in was $1.52. Therefore, Incyte's PE Ratio without NRI for today is 47.55.

During the past 13 years, Incyte's highest PE Ratio without NRI was 11323.00. The lowest was 15.32. And the median was 54.25.


Incyte Price-to-Owner-Earnings Historical Data

The historical data trend for Incyte's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 229.57 38.72 - 37.37 31.42

Incyte Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.37 41.09 45.19 32.41 31.42

Competitive Comparison

For the Biotechnology subindustry, Incyte's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Incyte Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Incyte's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Incyte's Price-to-Owner-Earnings falls in comparison to its industry or sector. The grey bar indicates the Price-to-Owner-Earnings's extreme value range as defined by GuruFocus.



Incyte Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Incyte's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=72.27/2.56
=28.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incyte  (NAS:INCY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Incyte Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Incyte's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte (NAS:INCY) Business Description

Incyte logo
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Executives
Susanne Schaffert director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Thomas Tray officer: Principal Accounting Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Katherine A High director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Edmund Harrigan director
Michael James Morrissey officer: EVP, Head of Tech. Operations IN CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Jonathan Elliott Dickinson officer: EVP, General Manager, Europe CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Christiana Stamoulis officer: EVP & Chief Financial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Maria E Pasquale officer: EVP & General Counsel C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Vijay K Iyengar officer: EVP GPS, BD, & Licensing 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Steven H Stein officer: EVP & Chief Medical Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul Trower officer: VP, Finance & Prin Acc Officer 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy director C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142

Incyte (NAS:INCY) Headlines